Android app on Google Play

Canaccord Genuity Reiterates a 'Buy' on Zalicus (ZLCS); Focus Shifts

September 11, 2012 8:22 AM EDT Send to a Friend
Get Alerts ZLCS Hot Sheet
Price: $1.18 --0%

Rating Summary:
    2 Buy, 4 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade ZLCS Now!
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Zalicus (NASDAQ: ZLCS) price target of $3.00.

Analyst, Ritu Baral, said, "Reiterate rating and price target despite Synavive Ph2b miss -- discontinuation shifts focus to pain programs that that we think have significantly more promise.. After today’s Synavive Ph2 miss and program halt...ZLCS will focus on Ph2 Z160, a novel, oral N-type Ca2+ channel blocker for neuropathic pain, and Ph1 pain drug Z944, a novel, oral T-type Ca2+ channel blocker."

For an analyst ratings summary and ratings history on Zalicus click here. For more ratings news on Zalicus click here.

Shares of Zalicus closed at $0.79 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments

Related Entities

Canaccord Genuity

Add Your Comment